Your browser doesn't support javascript.
loading
Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.
Barry, Abbie; Olsson, Sten; Khaemba, Christabel; Kabatende, Joseph; Dires, Tigist; Fimbo, Adam; Minzi, Omary; Bienvenu, Emile; Makonnen, Eyasu; Kamuhabwa, Appolinary; Oluka, Margaret; Guantai, Anastasia; van Puijenbroek, Eugène; Bergman, Ulf; Nkayamba, Alex; Mugisha, Michael; Gurumurthy, Parthasarathi; Aklillu, Eleni.
Afiliação
  • Barry A; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.
  • Olsson S; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.
  • Khaemba C; Pharmacy and Poisons Board, Kenya Lenana Road, P.O. Box 27663-00506 Nairobi, Kenya.
  • Kabatende J; Rwanda Food and Drugs Authority, Nyarutarama Plaza, KG 9 Avenue Kigali, Rwanda.
  • Dires T; Ethiopian Food and Drug Authority, Africa Avenue, Kirkos Sub City, P.O. Box 5681 Addis Ababa, Ethiopia.
  • Fimbo A; Tanzania Medicines and Medical Devices Authority, Off Mandela Road, Mabibo, P.O. Box 77150 Dar Es Salaam, Tanzania.
  • Minzi O; Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P. O. Box 65013 Dar es Salaam, Tanzania.
  • Bienvenu E; College of Medicine and Health Sciences, University of Rwanda, KK 737 Kigali, Rwanda.
  • Makonnen E; Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 9086 Addis Ababa, Ethiopia.
  • Kamuhabwa A; Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT Africa), College of Health Sciences, Addis Ababa University, P.O. Box 9086 Addis Ababa, Ethiopia.
  • Oluka M; Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P. O. Box 65013 Dar es Salaam, Tanzania.
  • Guantai A; Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O. Box 19676-00202 Nairobi, Kenya.
  • van Puijenbroek E; Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O. Box 19676-00202 Nairobi, Kenya.
  • Bergman U; Pharmacovigilance Centre Lareb, 5237 MH 's-Hertogenbosch, The Netherlands.
  • Nkayamba A; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.
  • Mugisha M; Tanzania Medicines and Medical Devices Authority, Off Mandela Road, Mabibo, P.O. Box 77150 Dar Es Salaam, Tanzania.
  • Gurumurthy P; College of Medicine and Health Sciences, University of Rwanda, KK 737 Kigali, Rwanda.
  • Aklillu E; Pharmacovigilance and Clinical Trials, Botswana Medicines Regulatory Authority, P.O. Box 505155 Gaborone, Botswana.
Article em En | MEDLINE | ID: mdl-33671293
ABSTRACT
Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND Problema de saúde: 3_neglected_diseases Assunto principal: Doenças Negligenciadas / Farmacovigilância Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Int J Environ Res Public Health Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND Problema de saúde: 3_neglected_diseases Assunto principal: Doenças Negligenciadas / Farmacovigilância Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Int J Environ Res Public Health Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia
...